Edgar Filing: BIOGEN INC. - Form 4


Form 4						
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue STATEMENT OF STATEMENT OF STATEMENT OF			CURITIES AND EXCHANGE Washington, D.C. 20549 HANGES IN BENEFICIAL O SECURITIES ion 16(a) of the Securities Excha ic Utility Holding Company Act he Investment Company Act of 1	Sind3235-0287Number:January 31, 2005Expires:2005Estimated average burden hours per response0.5		
(Print or Type I	Responses)					
1. Name and Address of Reporting Person <u>*</u> Clancy Paul J			Issuer Name and Ticker or Trading abol DGEN INC. [BIIB]	5. Relationship of Reporting Person(s) to Issuer		
(Last) (First) (Middle) BIOGEN INC., 225 BINNEY STREET			Date of Earliest Transaction onth/Day/Year) 115/2017	(Check all applicable) <u></u> Director <u></u> 10% Owner <u></u> X Officer (give title <u></u> Other (specify below) Executive VP and CFO		
			f Amendment, Date Original d(Month/Day/Year)	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 		
(City)	(State)	(Zip)	Table I. New Devineting Committing	Person	an Dan di si alla Orana d	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	-	Code Disposed of (D)	5. Amount of 6. Securities For Beneficially (I Owned (I Following (I Reported Transaction(s) (Instr. 3 and 4)	Ownership 7. Nature of orm: Direct Indirect O) or Indirect Beneficial	
Reminder: Ren	oort on a separate line	e for each class of	f securities beneficially owned directly	or indirectly.		

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onof Derivative	Expiration Date	Underlying Securities	Ε
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

Edgar Filing: BIOGEN INC. - Form 4



Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Clancy Paul J BIOGEN INC. 225 BINNEY STREET CAMBRIDGE, MA 02142			Executive VP and CFO		
Signatures					
Suzanne Murray, Attorney in F Clancy	act for Pa	ul	02/17/2017		
<u>**</u> Signature of Reporting Per	son		Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date.

(1) The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.